NEW YORK (GenomeWeb News) — Bio-Rad Laboratories said today that it plans to offer $250 million in a private overseas debt offering to raise funds for working capital, and general corporate purposes, including acquisitions.
The company said that the $250 million aggregate senior subordinated notes will be offered only to qualified institutional buyers and may not be sold inside the United States.